

Esra A Akbay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4382470/publications.pdf>

Version: 2024-02-01

27
papers

3,753
citations

331670

21
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

7820
citing authors

#	ARTICLE	IF	CITATIONS
1	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	6.5	29
2	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. <i>Cancer Research</i> , 2021, 81, 1813-1826.	0.9	41
3	Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 314.	4.4	44
4	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
5	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. <i>Science Immunology</i> , 2021, 6, eabc6424.	11.9	64
6	602...AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells. , 2021, 9, A632-A632.		0
7	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. <i>Nature Communications</i> , 2021, 12, 7014.	12.8	6
8	Dysfunctional telomeres trigger cellular senescence mediated by cyclic GMP-AMP synthase. <i>Journal of Biological Chemistry</i> , 2020, 295, 11144-11160.	3.4	32
9	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. <i>Nature Cancer</i> , 2020, 1, 394-409.	13.2	51
10	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>Cell Reports</i> , 2019, 27, 806-819.e5.	6.4	51
11	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
12	Identification and characterization of an alternative cancer-derived PD-L1 splice variant. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 407-420.	4.2	53
13	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. <i>Translational Lung Cancer Research</i> , 2018, 7, 464-486.	2.8	11
14	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4854-4864.	7.0	49
15	Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. <i>JCI Insight</i> , 2018, 3, .	5.0	156
16	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1268-1279.	1.1	152
17	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. <i>Nature Communications</i> , 2017, 8, 14922.	12.8	80
18	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.9	451

#	ARTICLE	IF	CITATIONS
19	The impact of the MYB-NFIB fusion proto-oncogene in vivo. <i>Oncotarget</i> , 2016, 7, 31681-31688.	1.8	11
20	Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. <i>Nature Communications</i> , 2014, 5, 5870.	12.8	44
21	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2014, 26, 909-922.	16.8	376
22	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. <i>Cancer Research</i> , 2014, 74, 4676-4684.	0.9	31
23	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014, 28, 479-490.	5.9	70
24	Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014, 513, 110-114.	27.8	367
25	Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression. <i>Cancer Cell</i> , 2014, 25, 590-604.	16.8	332
26	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. <i>Cancer Discovery</i> , 2013, 3, 1355-1363.	9.4	1,073
27	Differential Roles of Telomere Attrition in Type I and II Endometrial Carcinogenesis. <i>American Journal of Pathology</i> , 2008, 173, 536-544.	3.8	25